Angel Acquisitions Limited Form 8 (DD) - Healthcare Locums PLC (1077D)
April 24 2013 - 6:08AM
UK Regulatory
TIDMHLO
RNS Number : 1077D
Angel Acquisitions Limited
24 April 2013
FORM 8 (DD)
PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON
ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF
DISCRETIONARY INVESTMENT CLIENTS)
Rules 8.1, 8.2 and 8.4 of the Takeover Code (the "Code")
1. KEY INFORMATION
(a) Identity of the party to the offer or person acting in concert making the disclosure: Angel Acquisitions Ltd
--------------------------------------------------------------------------------------------- -----------------------
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):
The naming of nominee or vehicle companies is insufficient
--------------------------------------------------------------------------------------------- -----------------------
(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Healthcare Locums plc
Use a separate form for each offeror/offeree
--------------------------------------------------------------------------------------------- -----------------------
(d) Status of person making the disclosure: Offeror
e.g. offeror, offeree, person acting in concert with the offeror/offeree (specify name of
offeror/offeree)
--------------------------------------------------------------------------------------------- -----------------------
(e) Date dealing undertaken: 23 April 2013
--------------------------------------------------------------------------------------------- -----------------------
(f) Has the party previously disclosed, or is it today disclosing, under the Code in respect Yes
of any other party to this offer?
--------------------------------------------------------------------------------------------- -----------------------
2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE
(a) Interests and short positions in the relevant securities of
the offeror or offeree to which the disclosure relates following
the dealing
Class of relevant security:
-------------------------------------------------- -----------------------------------------
Interests Short positions
-------------------------------------------------- --------------------- ------------------
Number % Number %
-------------------------------------------------- ------------ ------- ------------- ---
(1) Relevant securities owned and/or controlled: 625,153,820 73.74%
-------------------------------------------------- ------------ ------- ------------- ---
(2) Derivatives (other than options):
-------------------------------------------------- ------------ ------- ------------- ---
(3) Options and agreements to purchase/sell:
-------------------------------------------------- ------------ ------- ------------- ---
TOTAL: 625,153,820 73.74%
-------------------------------------------------- ------------ ------- ------------- ---
All interests and all short positions should be disclosed.
Details of any open derivative or option positions, or
agreements to purchase or sell relevant securities, should be given
on a Supplemental Form 8 (Open Positions).
Details of any securities borrowing and lending positions or
financial collateral arrangements should be disclosed on a
Supplemental Form 8 (SBL).
(b) Rights to subscribe for new securities (including directors'
and other executive options)
Class of relevant security in relation to which subscription right exists:
----------------------------------------------------------------------------
Details, including nature of the rights concerned and relevant percentages:
----------------------------------------------------------------------------
If there are positions or rights to subscribe to disclose in
more than one class of relevant securities of the offeror or
offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for
each additional class of relevant security.
3. DEALINGS BY THE PERSON MAKING THE DISCLOSURE
(a) Purchases and sales
Class of relevant security Purchase/sale Number of securities Price per unit
---------------------------- --------------- --------------------- ---------------
Ords GBP 10p Purchase 1,733,600 0.75p
---------------------------- --------------- --------------------- ---------------
(b) Derivatives transactions (other than options)
Class of relevant Product description Nature of dealing Number of reference Price per unit
security e.g. CFD e.g. opening/closing a securities
long/short position,
increasing/reducing a
long/short position
------------------------- -------------------- ------------------------- ------------------------- ---------------
(c) Options transactions in respect of existing securities
(i) Writing, selling, purchasing or varying
Class of Product Writing, Number of Exercise Type Expiry date Option money
relevant description purchasing, securities price per e.g. paid/
security e.g. call selling, to which unit American, received per
option varying etc. option European unit
relates etc.
------------- ------------- ------------- ------------- -------------- ------------- ------------ -------------
(ii) Exercising
Class of relevant security Product description Number of securities Exercise price per unit
e.g. call option
--------------------------- -------------------- --------------------- ------------------------
(d) Other dealings (including subscribing for new securities)
Class of relevant security Nature of dealing Details Price per unit (if applicable)
e.g. subscription, conversion
--------------------------- ------------------------------- -------- -------------------------------
The currency of all prices and other monetary amounts should be
stated.
Where there have been dealings in more than one class of
relevant securities of the offeror or offeree named in 1(c), copy
table 3(a), (b), (c) or (d) (as appropriate) for each additional
class of relevant security dealt in.
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal
or informal, relating to relevant securities which may be an inducement to deal or refrain
from dealing entered into by the party to the offer or person acting in concert making the
disclosure and any other person:
If there are no such agreements, arrangements or understandings, state "none"
--------------------------------------------------------------------------------------------
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or informal, between the party
to the offer or person acting in concert making the disclosure and any other person relating
to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which
any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"
----------------------------------------------------------------------------------------------
(c) Attachments
Are any Supplemental Forms attached?
Supplemental Form 8 (Open Positions) NO
------------------------------------- ---
Supplemental Form 8 (SBL) NO
------------------------------------- ---
Date of disclosure: 24 April 2013
--------------------- --------------
Contact name: David Baker
--------------------- --------------
Telephone number: 020-7523-4656
--------------------- --------------
Public disclosures under Rule 8 of the Code must be made to a
Regulatory Information Service and must also be emailed to the
Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market
Surveillance Unit is available for consultation in relation to the
Code's dealing disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at
www.thetakeoverpanel.org.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DCCSEWFSLFDSESL
Healthcare Locums (LSE:HLO)
Historical Stock Chart
From Oct 2024 to Nov 2024
Healthcare Locums (LSE:HLO)
Historical Stock Chart
From Nov 2023 to Nov 2024
